Founded in 1998, Hybio is a leading peptides company in China specializing in the development, manufacture and commercialization of therapeutic peptides API and peptide-based drugs, listed in market with stock code 300199.
With more than 20 years’ experience, Hybio offers a full range of synthetic peptide products and services, as well as CRO and CDMO for research, clinical development and commercial application for pharmaceutical companies worldwide. The main products have been applied to treat the digestive diseases, cardio-cerebro-vascular diseases, diabetes, infectious disease, cancer, and senile diseases, etc.
We offer a full range of peptides globally, such as Liraglutide, Semaglutide and Exenatide for diabetes; Terlipressin, Desmopressin and Linaclotide for digestive tract and metabolic system; Ganirelix, Cetrorelix and Atosiban for obstetrics and gynecology, etc.
Hybio Pharmaceutical (Wuhan) Co., Ltd is a subsidiary of Hybio Group, it locates in Huangpi district of Wuhan City with around 200 employees in total. With a total investment over US$1 billion, an overall construction area of 250,000 square meters under cGMP standard, Hybio Wuhan was completed and put into use in second half of 2018. As a new factory, it consists of four parts including Peptide APIs site, Oral Solid Dosage site, Biopharma site and Service Center site. Equipped with the comprehensive facilities, Hybio Wuhan provides full range of peptide products and all-round services to satisfy customers internationally.
Over the years, Hybio has passed inspections from overseas and Chinese authorities and customers for an accumulated 150 times, covering its Shenzhen API site, Wuhan API site and Pingshan FDF site.
See you at CPhI China 2022 in Shanghai!
Hybio obtained the CEP from EDQM for Oxytocin
Exciting News! Hybio and Ferring China has signed strategic contract to promote the commercialization of Cetrorelix Acetate for Injection in China market on Thursday-August 26, 2021.